Celltrion is expanding its market presence in Peru, a major Latin American country, by winning a series of successful public tenders.First of all, Truxima (rituximab) 500 mg won a tender held by the National Health Ministry of Peru (Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud
Celltrion’s biosimilar products for the treatment of autoimmune diseases have successively won bids in major European countries.According to Celltrion on Jan. 12, Yuflyma (active ingredient: adalimumab) has successfully won a government bid in Italy. Yuflyma was awarded in the adalimumab government
On Dec. 28, the integrated company Celltrion will be officially launched. Celltrion is taking steps to leap into a global big pharmaceutical firm by merging with Celltrion Healthcare, which is responsible for global distribution.Celltrion and Celltrion Healthcare announced on Dec. 27 that they are i
Celltrion Healthcare is expanding its presence in the United States, the world's largest pharmaceutical market, with its biosimilar of Avastin for metastatic colorectal and breast cancer, known as Vegzelma (active ingredient: bevacizumab).On Dec. 12, Celltrion Healthcare announced that Vegzelma was
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Celltrion Healthcare posted sound 3Q23 earnings, when considering purchase price settlements. Defying market concerns, the company showed a relative return of 15%p following its merger disclosure on
In March 2021, Seo Jung-jin, the honorary chairman of Celltrion, declared his retirement, stating, “If there are any deficiencies in management, I will be prepared to play a firefighter’s role.” However, just two years later, in March of this year, he made a surprising announcement of his return to
Seo Jung-jin, chairman of Celltrion Group, met with foreign investors and institutional partners to present the blueprint for the group’s merger and its future vision. On Sept. 11 (local time) in New York, Chairman Seo attended the “21st Morgan Stanley Global Healthcare Conference” where he had a di
Celltrion announced on Sept. 4 that it recently obtained sales approval for its Avastin (bevacizumab) biosimilar Vegzelma from the Australian Therapeutic Goods Administration (TGA).Celltrion has been granted sales approval for Vegzelma in Australia for the entire range of indications approved for Av
On Aug. 31, Celltrion announced it has completed the product approval application for its autoimmune disease therapeutic “CT-P43,” a biosimilar of STELARA (ustekinumab), to Australia’s Therapeutic Goods Administration (TGA).Celltrion applied for CT-P43’s product approval in Australia for all indicat
On Aug. 17, Celltrion Inc. announced its decision to merge with Celltrion Healthcare Co. Through its disclosure, Celltrion explained that the decision to merge was made to integrate assets for large-scale investments, enhance cost competitiveness through the integration of development, production, a
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Truxima’s US market share reached its highest level in 1Q23, but the drug’s quarterly price drop was also the largest in the past three years. We expect earnings growth to centere on Remsima SC in 2H
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.We estimate Celltrion’s 2Q23 OP at W193.2bn, slightly below consensus. We trim our annual earnings projections to reflect Truxima price decline in the US. Although Remsima SC earnings likely came in
The author is an analyst for Shinhan Securities. He can be reached at jaewonjeong@shinhan.com -- Ed.Pharmaceutical/bio sector to rebound in 2H23 on favorable macro conditions and progress in new drug pipelinesPharmaceutical/bio stocks have fallen out of investors’ favor with valuations declining on
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Although its 1Q23 sales declined q-q, Celltrion Healthcare achieved: 1) its highest quarterly GPM; and 2) expanded M/S for both Remsima IV and SC in Europe. Anticipating sales expansion towards 2H23,
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.We raise our TP on Celltrion to 240,000, as we hike our GPM forecast. Excluding compensation costs of W60bn for US Covid-19 test kits, 1Q23 GPM came to 54%, beating consensus. GPM normalization and F
The author is an analysts of NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.At Celltrion Healthcare, 1Q23 OP should arrive in line with consensus at W63.6bn. Significant sales growth was confirmed for all major items in US prescription data for March. Although one-off cost i
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed.Celltrion Healthcare’s 4Q22 OP should slightly miss consensus due to expenses related to partner company compensation in Europe and incentive payment. While 2023 should be dedicated to preparation for
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed.We expect Celltrion to post 4Q22 OP of W187.8bn, remaining roughly in line with our estimate, but missing consensus. The firm should report steady growth in 2023, backed by additional sales of Remsima
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed.US market prescription trends proved stable m-m in December. The US market shares of most domestic biosimilar players have been widening as of late, but further decline in their ASPs is being seen in
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Celltrion Healthcare’s OP for 3Q22 satisfied consensus if stripping out one-off costs. We see 2022E OP of W283.9bn, driven by Remsima IV/SC sales growth in the US and EU markets. If it mainly targets